Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Botteman · SciRah

Researcher profile · Semantic Scholar

M. Botteman

Share profile

M. Botteman — researcher profile on SciRah

h-index: 41
Works: 317
Citations: 7,052

Most-cited papers

Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report.
A. Wailoo, Mónica Hernández-Alava, A. Manca, A. Mejía +4 more
2017Value in Health199 citations Open access
Semantic Scholar
Estimating the global prevalence of transthyretin familial amyloid polyneuropathy
H. Schmidt, M. Waddington‐Cruz, M. Botteman, J. Carter +5 more
2018Muscle and Nerve197 citations Open access
Semantic Scholar
Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
M. Waddington‐Cruz, H. Schmidt, M. Botteman, J. Carter +4 more
2019Orphanet Journal of Rare Diseases58 citations Open access
Semantic Scholar
Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis
C. Solem, M. Vera-Llonch, Sizhu Liu, M. Botteman +1 more
2016Health and Quality of Life Outcomes48 citations Open access
Semantic Scholar
Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma
A. Aly, Courtney Johnson, Shuo Yang, M. Botteman +2 more
2019Journal of Medical Economics44 citations Open access
Semantic Scholar
Long-Term Assessment of Healthcare Utilization Five Years After Respiratory Syncytial Virus Infection in US Infants.
E. Simőes, V. Chirikov, M. Botteman, Youngmin Kwon +1 more
2019Journal of Infectious Diseases38 citations Open access
Semantic Scholar
Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?
M. Postma, D. Noone, M. Rozenbaum, J. Carter +3 more
2022Orphanet Journal of Rare Diseases36 citations Open access
Semantic Scholar
Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States
Rongzhe Liu, Olalekan O. Oluwole, I. Diakite, M. Botteman +2 more
2021Journal of Medical Economics34 citations Open access
Semantic Scholar
Corneal cross-linking versus conventional management for keratoconus: a lifetime economic model
R. Lindstrom, John P. Berdahl, E. Donnenfeld, V. Thompson +6 more
2020Journal of Medical Economics33 citations Open access
Semantic Scholar
Systematic review and benchmarking of Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) in oncology
C. Solem, Youngmin Kwon, R. Shah, A. Aly +1 more
2018Expert review of pharmacoeconomics & outcomes research32 citations
Semantic Scholar
A Canadian Cost-Utility Analysis of 2 Trabecular Microbypass Stents at Time of Cataract Surgery in Patients with Mild to Moderate Open-Angle Glaucoma.
I. I. Ahmed, D. Podbielski, V. Patel, H. Falvey +3 more
2020Ophthalmology Glaucoma28 citations Open access
Semantic Scholar
Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment
S. Srinivas, A. Mohamed, S. Appukkuttan, M. Botteman +6 more
2020Cancer Medicine28 citations Open access
Semantic Scholar
Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy
A. Shah, R. Shah, N. Kebede, A. Mohamed +3 more
2019Journal of Medical Economics28 citations Open access
Semantic Scholar
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis
U. Pelzer, J. Blanc, D. Melisi, A. Cubillo +10 more
2017British Journal of Cancer27 citations Open access
Semantic Scholar
Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer.
A. Aly, R. Shah, K. Hill, M. Botteman
2019Future Oncology26 citations Open access
Semantic Scholar
Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis
M. Botteman, K. Nickel, S. Corman, M. Turini +1 more
2019Supportive Care in Cancer25 citations Open access
Semantic Scholar
The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis
A. Aly, Courtney Johnson, Y. Doleh, Viktor Chirikov +3 more
2020Journal of Clinical Pathways23 citations Open access
Semantic Scholar
Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Perspectives on Treatment.
A. Zeidan, Sayeli Jayade, J. Schmier, M. Botteman +4 more
2021Clinical Lymphoma, Myeloma & Leukemia22 citations Open access
Semantic Scholar
Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy
T. Macarulla, A. Hendifar, Chung-Pin Li, M. Reni +7 more
2019Pancreas21 citations Open access
Semantic Scholar
Economic Burden Trajectories in Commercially Insured US Infants with Respiratory Syncytial Virus.
V. Chirikov, E. Simőes, A. Kuznik, Youngmin Kwon +1 more
2019Journal of Infectious Diseases21 citations
Semantic Scholar
Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel
Corey J. Langer, V. Hirsh, I. Okamoto, F. Lin +5 more
2015British Journal of Cancer20 citations Open access
Semantic Scholar
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
S. Srinivas, A. Mohamed, S. Appukkuttan, M. Botteman +5 more
2020BMC Urology19 citations Open access
Semantic Scholar
Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes.
A. Zeidan, J. Tsai, M. Karimi, J. Schmier +8 more
2022Clinical Lymphoma, Myeloma & Leukemia17 citations Open access
Semantic Scholar
Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients
Sha-yi Jiang, K. Hill, D. Patel, A. Waldeck +3 more
2017Journal of Medical Economics17 citations Open access
Semantic Scholar
Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy
A. González-Duarte, I. Conceição, L. Amass, M. Botteman +2 more
2020Neurological Therapeutics16 citations Open access
Semantic Scholar
A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)
R. Shah, M. Botteman, C. Solem, L. Luo +3 more
2019Clinical Genitourinary Cancer16 citations Open access
Semantic Scholar
Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
D. McDermott, R. Shah, K. Gupte-Singh, J. Sabater +5 more
2018Quality of Life Research16 citations
Semantic Scholar
Patient and caregiver preferences for haemophilia A treatments: A discrete choice experiment
Jun Su, Nan-Xin Li, N. Joshi, Xin-Yi Ng +5 more
2020Haemophilia14 citations
Semantic Scholar
Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review
H. Schmidt, M. Cruz, M. Botteman, J. Carter +5 more
2017Amyloid: Journal of Protein Folding Disorders14 citations
Semantic Scholar
Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey
D. George, A. Mohamed, J. Tsai, M. Karimi +3 more
2022Cancer Medicine12 citations Open access
Semantic Scholar
Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study.
A. Aly, Prianka Singh, B. Korytowsky, Y.-L. Ling +4 more
2019Neuro-Oncology Practice12 citations Open access
Semantic Scholar
Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: a global synthesis of 532 cases
M. Cruz, H. Schmidt, M. Botteman, J. Carter +5 more
2017Amyloid: Journal of Protein Folding Disorders12 citations
Semantic Scholar
Quality‐Adjusted Survival With nab‐Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q‐TWiST Analysis
J. Cortés, J. Pérez-García, S. Whiting, Y. Wan +6 more
2018Clinical Breast Cancer11 citations Open access
Semantic Scholar
Healthcare Burden and Costs Associated with Urinary Tract Infections in Type 2 Diabetes Mellitus Patients: An Analysis Based on a Large Sample of 456,586 German Patients
T. Wilke, Björn Böttger, Bjorn P. Berg, A. Groth +4 more
2016Nephron11 citations
Semantic Scholar
Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer
D. Goldstein, D. V. Von Hoff, E. Chiorean, M. Reni +9 more
2020Pancreas10 citations Open access
Semantic Scholar
Treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan.
R. Shah, M. Botteman, R. Waldeck
2019Future Oncology10 citations Open access
Semantic Scholar
The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making.
A. Waldeck, M. Botteman, R. White, B. van Hout
2017Journal of Managed Care & Specialty Pharmacy9 citations Open access
Semantic Scholar
Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma
M. Reni, J. Braverman, A. Hendifar, Chung-Pin Li +9 more
2021Annals of Surgical Oncology8 citations
Semantic Scholar
Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting
Sang Hee Park, G. Binder, S. Corman, M. Botteman
2019Journal of Medical Economics8 citations Open access
Semantic Scholar
Economic value of using partially hydrolysed infant formula for risk reduction of atopic dermatitis in high-risk, not exclusively breastfed infants in Singapore.
M. Botteman, A. Bhanegaonkar, E. Horodniceanu, Xiang Ji +4 more
2018Singapore medical journal8 citations Open access
Semantic Scholar
The Long-Term Healthcare Utilization and Economic Burden of RSV Infection in Children ≤5 Years in Japan: Propensity Score Matched Cohort Study
V. Chirikov, M. Botteman, E. Simões
2022ClinicoEconomics and Outcomes Research7 citations Open access
Semantic Scholar
Economic value of atopic dermatitis prevention via partially-hydrolyzed whey-based infant formula (PHF-W) use in high-risk, non-exclusively breastfed, Indonesian urban infants: results of a cost-effectiveness model
M. Botteman, Z. Munasir, A. Sulistomo, E. Horodniceanu +5 more
2019World Nutrition Journal7 citations Open access
Semantic Scholar
Economic value of atopic dermatitis prevention via infant formula use in high-risk Malaysian infants
A. Bhanegaonkar, E. Horodniceanu, A. A. Abdul Latiff, S. Woodhull +4 more
2015Asia Pacific Allergy7 citations Open access
Semantic Scholar
Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant
Hrishikesh P. Kale, Z. Qureshi, R. Shah, R. Khandker +3 more
2021Advances in Therapy6 citations Open access
Semantic Scholar
A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC).
R. Sugarman, M. Botteman, N. Rusibamayila, Hiep Nguyen +1 more
2022Journal of Clinical Oncology5 citations
Semantic Scholar
Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
E. Chiorean, D. V. Von Hoff, Y. Wan, Sandra Margunato‐Debay +2 more
2018Cancer Management and Research5 citations Open access
Semantic Scholar
nab‐Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial
R. Young, P. Mainwaring, P. Clingan, Francis X. Parnis +8 more
2018Asia-Pacific Journal of Clinical Oncology5 citations
Semantic Scholar
194 - Estimating Population-Level Prevalence of Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy
M. Grogan, F. A. D. Siepen, J. Carter, M. Botteman +3 more
20175 citations
Semantic Scholar
Economic Burden of Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the US
A. Aly, B. Bapat, S. Ray, Zhi-Yong Chen +1 more
20174 citations
Semantic Scholar
Physician benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC).
S. Srinivas, A. Mohamed, S. Appukkuttan, M. Botteman +5 more
2019Journal of Clinical Oncology3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Aly×9
Invite
A. Aly — researcher profile on SciRah
J. Carter×8
Invite
J. Carter — researcher profile on SciRah
R. Shah×7
Invite
R. Shah — researcher profile on SciRah
M. Stewart×6
Invite
M. Stewart — researcher profile on SciRah

×6

Invite

N. Joshi — researcher profile on SciRah

Invite

M. Hopps — researcher profile on SciRah

Invite

L. Amass — researcher profile on SciRah

Invite

C. Solem — researcher profile on SciRah

Invite

A. Mohamed — researcher profile on SciRah

E. Horodniceanu×5

Invite

E. Horodniceanu — researcher profile on SciRah

Invite

H. Schmidt — researcher profile on SciRah

Invite

S. Fallet — researcher profile on SciRah